O	0	4	Late
O	5	13	extended
O	14	22	adjuvant
O	23	32	treatment
O	33	37	with
B-intervention	38	47	letrozole
O	48	56	improves
O	57	64	outcome
O	65	67	in
B-eligibility	68	73	women
I-eligibility	74	78	with
I-eligibility	79	84	early
I-eligibility	84	85	-
I-eligibility	85	90	stage
I-eligibility	91	97	breast
I-eligibility	98	104	cancer
I-eligibility	105	108	who
I-eligibility	109	117	complete
I-eligibility	118	119	5
I-eligibility	120	125	years
I-eligibility	126	128	of
I-eligibility	129	138	tamoxifen
O	138	139	.

O	140	143	The
O	144	152	National
O	153	159	Cancer
O	160	169	Institute
O	170	172	of
B-location	173	179	Canada
O	180	188	Clinical
O	189	195	Trials
O	196	201	Group
O	202	204	MA
O	204	205	.
O	205	207	17
O	208	213	trial
O	214	222	examined
O	223	226	the
O	227	235	efficacy
O	236	238	of
O	239	248	letrozole
O	249	250	(
O	250	253	LET
O	253	254	)
O	255	262	started
O	263	269	within
O	270	271	3
O	272	278	months
O	279	281	of
O	282	283	5
O	284	289	years
O	290	292	of
O	293	301	adjuvant
O	302	311	tamoxifen
O	312	314	in
O	315	329	postmenopausal
O	330	337	hormone
O	338	346	receptor
O	346	347	-
O	347	355	positive
O	356	361	early
O	361	362	-
O	362	367	stage
O	368	374	breast
O	375	381	cancer
O	381	382	.

O	383	387	When
O	388	391	the
O	392	397	trial
O	398	401	was
O	402	411	unblinded
O	411	412	,
O	413	421	patients
O	422	425	who
O	426	434	received
B-control	435	442	placebo
I-control	443	444	(
I-control	444	448	PLAC
I-control	448	449	)
O	450	454	were
O	455	462	offered
O	463	466	LET
O	466	467	.

O	468	472	This
O	473	479	cohort
O	480	488	analysis
O	489	498	describes
O	499	502	the
O	503	511	outcomes
O	512	514	of
O	515	520	women
O	521	529	assigned
O	530	534	PLAC
O	535	537	at
O	538	541	the
O	542	549	initial
O	550	556	random
O	557	567	assignment
O	568	573	after
O	574	584	unblinding
O	584	585	.

O	586	594	Efficacy
O	595	603	outcomes
O	604	606	of
O	607	612	women
O	613	616	who
O	617	622	chose
O	623	626	LET
O	627	628	(
O	628	632	PLAC
O	632	633	-
O	633	636	LET
O	637	642	group
O	642	643	)
O	644	648	were
O	649	657	compared
O	658	662	with
O	663	668	those
O	669	672	who
O	673	676	did
O	677	680	not
O	681	682	(
O	682	686	PLAC
O	686	687	-
O	687	691	PLAC
O	692	697	group
O	697	698	)
O	699	701	by
O	702	705	the
O	706	712	hazard
O	713	719	ratios
O	720	723	and
O	724	726	by
O	727	728	P
O	729	735	values
O	736	746	calculated
O	747	751	from
O	752	755	Cox
O	756	762	models
O	763	767	that
O	768	776	adjusted
O	777	780	for
O	781	791	imbalances
O	792	799	between
O	800	803	the
O	804	810	groups
O	810	811	.

O	812	820	Toxicity
O	821	829	analyses
O	830	838	included
O	839	843	only
O	844	850	events
O	851	855	that
O	856	864	occurred
O	865	870	after
O	871	881	unblinding
O	881	882	.

O	883	888	There
O	889	893	were
B-intervention-participants	894	895	1
I-intervention-participants	895	896	,
I-intervention-participants	896	899	579
O	900	905	women
O	906	908	in
O	909	912	the
O	913	917	PLAC
O	917	918	-
O	918	921	LET
O	922	927	group
O	928	929	(
O	929	935	median
O	936	940	time
O	941	945	from
O	946	955	tamoxifen
O	955	956	,
O	957	958	2
O	958	959	.
O	959	960	8
O	961	966	years
O	966	967	)
O	968	971	and
B-control-participants	972	975	804
O	976	978	in
O	979	982	the
O	983	987	PLAC
O	987	988	-
O	988	992	PLAC
O	993	998	group
O	998	999	.

O	1000	1008	Patients
O	1009	1011	in
O	1012	1015	the
O	1016	1020	PLAC
O	1020	1021	-
O	1021	1024	LET
O	1025	1030	group
O	1031	1035	were
O	1036	1043	younger
O	1043	1044	;
O	1045	1048	had
O	1049	1050	a
O	1051	1057	better
O	1058	1069	performance
O	1070	1076	status
O	1076	1077	;
O	1078	1081	and
O	1082	1086	were
B-outcome	1087	1091	more
I-outcome	1092	1098	likely
I-outcome	1099	1101	to
I-outcome	1102	1106	have
I-outcome	1107	1110	had
I-outcome	1111	1115	node
I-outcome	1115	1116	-
I-outcome	1116	1124	positive
I-outcome	1125	1132	disease
O	1132	1133	,
B-outcome	1134	1142	axillary
I-outcome	1143	1153	dissection
O	1153	1154	,
O	1155	1158	and
B-outcome	1159	1167	adjuvant
I-outcome	1168	1180	chemotherapy
O	1181	1185	than
O	1186	1191	those
O	1192	1194	in
O	1195	1198	the
O	1199	1203	PLAC
O	1203	1204	-
O	1204	1208	PLAC
O	1209	1214	group
O	1214	1215	.

O	1216	1218	At
O	1219	1220	a
O	1221	1227	median
O	1228	1234	follow
O	1234	1235	-
O	1235	1237	up
O	1238	1240	of
O	1241	1242	5
O	1242	1243	.
O	1243	1244	3
O	1245	1250	years
O	1250	1251	,
B-outcome	1252	1259	disease
I-outcome	1259	1260	-
I-outcome	1260	1264	free
I-outcome	1265	1273	survival
O	1274	1275	(
O	1275	1278	DFS
O	1278	1279	;
O	1280	1288	adjusted
O	1289	1295	hazard
O	1296	1301	ratio
O	1302	1303	[
O	1303	1305	HR
O	1305	1306	]
O	1306	1307	,
O	1308	1309	0
O	1309	1310	.
O	1310	1312	37
O	1312	1313	;
O	1314	1316	95
O	1316	1317	%
O	1318	1320	CI
O	1320	1321	,
O	1322	1323	0
O	1323	1324	.
O	1324	1326	23
O	1327	1329	to
O	1330	1331	0
O	1331	1332	.
O	1332	1334	61
O	1334	1335	;
O	1336	1337	P
O	1338	1339	<
O	1340	1341	.
O	1341	1345	0001
O	1345	1346	)
O	1347	1350	and
B-outcome	1351	1358	distant
I-outcome	1359	1362	DFS
O	1363	1364	(
O	1364	1366	HR
O	1366	1367	,
O	1368	1369	0
O	1369	1370	.
O	1370	1372	39
O	1372	1373	;
O	1374	1376	95
O	1376	1377	%
O	1378	1380	CI
O	1380	1381	,
O	1382	1383	0
O	1383	1384	.
O	1384	1386	20
O	1387	1389	to
O	1390	1391	0
O	1391	1392	.
O	1392	1394	74
O	1394	1395	;
O	1396	1397	P
O	1398	1399	=
O	1400	1401	.
O	1401	1404	004
O	1404	1405	)
O	1406	1410	were
O	1411	1419	superior
O	1420	1422	in
O	1423	1426	the
O	1427	1431	PLAC
O	1431	1432	-
O	1432	1435	LET
O	1436	1441	group
O	1441	1442	.

O	1443	1447	More
O	1448	1452	self
O	1452	1453	-
O	1453	1461	reported
O	1462	1465	new
O	1466	1475	diagnoses
O	1476	1478	of
B-outcome	1479	1491	osteoporosis
I-outcome	1492	1495	and
I-outcome	1496	1509	significantly
I-outcome	1510	1514	more
I-outcome	1515	1523	clinical
I-outcome	1524	1533	fractures
O	1534	1542	occurred
O	1543	1545	in
O	1546	1549	the
O	1550	1555	women
O	1556	1559	who
O	1560	1564	took
O	1565	1568	LET
O	1569	1570	(
B-iv-bin-percent	1570	1571	5
I-iv-bin-percent	1571	1572	.
I-iv-bin-percent	1572	1573	2
I-iv-bin-percent	1573	1574	%
O	1575	1576	v
B-cv-bin-percent	1577	1578	3
I-cv-bin-percent	1578	1579	.
I-cv-bin-percent	1579	1580	1
I-cv-bin-percent	1580	1581	%
O	1581	1582	,
O	1583	1584	P
O	1585	1586	=
O	1587	1588	.
O	1588	1590	02
O	1590	1591	)
O	1591	1592	.

O	1593	1607	Interpretation
O	1608	1610	of
O	1611	1615	this
O	1616	1622	cohort
O	1623	1631	analysis
O	1632	1640	suggests
O	1641	1645	that
O	1646	1649	LET
O	1650	1658	improves
O	1659	1662	DFS
O	1663	1666	and
O	1667	1674	distant
O	1675	1678	DFS
O	1679	1683	even
O	1684	1688	when
O	1689	1694	there
O	1695	1698	has
O	1699	1703	been
O	1704	1705	a
O	1706	1717	substantial
O	1718	1724	period
O	1725	1727	of
O	1728	1732	time
O	1733	1738	since
O	1739	1742	the
O	1743	1758	discontinuation
O	1759	1761	of
O	1762	1767	prior
O	1768	1776	adjuvant
O	1777	1786	tamoxifen
O	1786	1787	.
